Investor Presentation Full Year 2021
44
Investor presentation
Full year 2021
Glargine U100
Change
9
*
*
in HbA1c
8
7
16
M
0.0
-0.2
Icodec, a once-weekly insulin, improved PPG control, HbA1c, and
increased the number of patients reaching target in a phase 2 trial
Icodec showed statistically significant
post prandial blood glucose control
FPG
(mmol/L)
Icodec
Numerical improvement in HbA1c
Icodec
The proportion of patients on Icodec
reaching HbA1c targets was higher
over 26 weeks
Glargine U100
Proportion
of patients
100%
Icodec
Glargine U100
Novo NordiskⓇ
-0.4
72%
75%
68%
-0.6
-0.8
-1.0
5
Breakfast
+90 min
Lunch
+90 min
Evening meal
-1.2
+90 min
Bedtime
04:00
Breakfast next day
-1.4
50%
-1.15
25%
-1.33
49%
39%
-1.6
0%
048
12 16 20
26
Weeks
< 7.0%
≤ 6.5%
HbA1c target
*Statistically significant at week 26
PPG: Post-prandial control; FPG: Fasting plasma glucoseView entire presentation